E-Scopics Receives FDA 510(k) Clearance for Hepatoscope-Derived Fat Fraction (HDFF) to Further Expand the Accessibility of Point-of-Care Non-Invasive Assessment of Fatty Liver

Key Takeaways:

• FDA clearance verifies the safety and efficiency of HDFF.
• HDFF integrates ultrasound attenuation and backscattering coefficient.
• A 0.93 correlation coefficient with MRI-PDFF underscores reliable results.
• The non-invasive nature of HDFF could broaden patient access.
• This technology signals potential progress in identifying and managing fatty liver disease.

Understanding HDFF

E-Scopics, a pioneering force in advanced point-of-care liver imaging, recently gained FDA 510(k) clearance for its Hepatoscope-Derived Fat Fraction (HDFF). This newly cleared technology aims to improve the speed and accessibility of non-invasive evaluations of fatty liver disease, an increasingly common health concern worldwide.

FDA Clearance

FDA 510(k) clearance is a critical milestone, indicating that a medical device is considered safe and effective. In this case, HDFF’s clearance means healthcare providers could soon have expanded access to point-of-care liver assessment tools that may streamline the diagnostic process for patients.

Clinical Correlation

One compelling aspect of HDFF is its correlation coefficient of 0.93 (with a 95% confidence interval of 0.89-0.95) when measured against MRI-PDFF, which is widely recognized as a standard reference. This high correlation highlights the device’s accuracy and potential reliability in everyday clinical use.

Innovative Ultrasound Parameters

At the heart of HDFF is a combination of ultrasound attenuation and backscattering coefficient. These quantitative ultrasound parameters were already part of E-Scopics’ imaging system, but bringing them together in HDFF provides what the company describes as a more comprehensive insight into fatty liver content—without the need for more invasive diagnostics.

Future Accessibility

By capitalizing on existing point-of-care technology, HDFF could broaden the reach of non-invasive liver assessments, ensuring those at risk receive timely evaluations. E-Scopics views this shift as a way to further democratize the monitoring of liver health, facilitating earlier interventions and potentially improving patient outcomes.

Industry Relevance

With fatty liver disease on the rise, advancements like HDFF represent a vital step forward. While MRI-PDFF remains a respected reference method, it can be costly and less accessible in certain areas. The availability of HDFF may reduce both patient burden and diagnostic hurdles, giving healthcare professionals an important tool to identify and track liver fat more efficiently.

By merging precise ultrasound-based measurements and FDA-cleared reliability, E-Scopics’ HDFF technology stands out as a promising breakthrough in the global effort to deliver accessible, accurate, and timely liver disease diagnosis.